Human immunodeficiency virus type 1 biological variation and coreceptor use: from concept to clinical significance.
Fenyö, Eva Maria LU ; Esbjörnsson, Joakim LU
; Medstrand, Patrik
LU
and Jansson, Marianne
LU
(2011)
In Journal of Internal Medicine
270.
p.520-531
- Abstract
- There is ample evidence for intra-patient evolution of the human immunodeficiency virus type 1 (HIV-1) biological phenotype during the pathogenic process. Evolution often involves switch of coreceptor use from CCR5 to CXCR4, but change to more flexible use of CCR5 occurs over time even in patients with maintained CCR5 use. The increasing use of entry inhibitors in the clinic, often specific for one or the other HIV-1 coreceptor or with different binding properties to CCR5, calls for virus testing in patients prior to treatment initiation. Cell lines expressing CCR5/CXCR4 chimeric receptors are tools for testing viruses for mode of CCR5 use. It is conceivable that small-molecule entry inhibitors that differentially bind to CCR5 can be... (More)
- There is ample evidence for intra-patient evolution of the human immunodeficiency virus type 1 (HIV-1) biological phenotype during the pathogenic process. Evolution often involves switch of coreceptor use from CCR5 to CXCR4, but change to more flexible use of CCR5 occurs over time even in patients with maintained CCR5 use. The increasing use of entry inhibitors in the clinic, often specific for one or the other HIV-1 coreceptor or with different binding properties to CCR5, calls for virus testing in patients prior to treatment initiation. Cell lines expressing CCR5/CXCR4 chimeric receptors are tools for testing viruses for mode of CCR5 use. It is conceivable that small-molecule entry inhibitors that differentially bind to CCR5 can be matched for best effect against HIV-1 with different modes of CCR5 use, thereby allowing an individualized drug choice specifically tailored for each patient. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/2168780
- author
- Fenyö, Eva Maria
LU
; Esbjörnsson, Joakim
LU
; Medstrand, Patrik
LU
and Jansson, Marianne
LU
- organization
- publishing date
- 2011
- type
- Contribution to journal
- publication status
- published
- subject
- in
- Journal of Internal Medicine
- volume
- 270
- pages
- 520 - 531
- publisher
- Wiley-Blackwell
- external identifiers
-
- wos:000297865300003
- pmid:21929694
- scopus:81855208925
- pmid:21929694
- ISSN
- 1365-2796
- DOI
- 10.1111/j.1365-2796.2011.02455.x
- language
- English
- LU publication?
- yes
- additional info
- The information about affiliations in this record was updated in December 2015. The record was previously connected to the following departments: Division of Medical Microbiology (013250400), Molecular Virology (013212007)
- id
- f80d15ca-0806-4fe5-a376-5874b6a00a91 (old id 2168780)
- alternative location
- http://www.ncbi.nlm.nih.gov/pubmed/21929694?dopt=Abstract
- date added to LUP
- 2016-04-04 09:05:06
- date last changed
- 2022-02-28 06:16:15
@article{f80d15ca-0806-4fe5-a376-5874b6a00a91,
abstract = {{There is ample evidence for intra-patient evolution of the human immunodeficiency virus type 1 (HIV-1) biological phenotype during the pathogenic process. Evolution often involves switch of coreceptor use from CCR5 to CXCR4, but change to more flexible use of CCR5 occurs over time even in patients with maintained CCR5 use. The increasing use of entry inhibitors in the clinic, often specific for one or the other HIV-1 coreceptor or with different binding properties to CCR5, calls for virus testing in patients prior to treatment initiation. Cell lines expressing CCR5/CXCR4 chimeric receptors are tools for testing viruses for mode of CCR5 use. It is conceivable that small-molecule entry inhibitors that differentially bind to CCR5 can be matched for best effect against HIV-1 with different modes of CCR5 use, thereby allowing an individualized drug choice specifically tailored for each patient.}},
author = {{Fenyö, Eva Maria and Esbjörnsson, Joakim and Medstrand, Patrik and Jansson, Marianne}},
issn = {{1365-2796}},
language = {{eng}},
pages = {{520--531}},
publisher = {{Wiley-Blackwell}},
series = {{Journal of Internal Medicine}},
title = {{Human immunodeficiency virus type 1 biological variation and coreceptor use: from concept to clinical significance.}},
url = {{http://dx.doi.org/10.1111/j.1365-2796.2011.02455.x}},
doi = {{10.1111/j.1365-2796.2011.02455.x}},
volume = {{270}},
year = {{2011}},
}